Rtw Investments Reduces $71M in Cogent Biosciences, Inc. ($COGT)

RTW Investments reduced its stake in Cogent Biosciences, reflecting in its latest SEC filing.

Written by Trueearnings · Published Jun 14, 2026, 4:55 AM EDT

Key Points

RTW Investments cut its holdings in Cogent Biosciences by 28.1%, selling 2,133,566 shares and retaining 5,458,675 shares valued at $180.7 million.
Cogent Biosciences, trading at $33.10, has a market cap of $5.66 billion and a forward P/E ratio indicating no profit yet.
Analysts maintain a strong buy consensus with an average target price of $54.25, while insiders recently bought shares.

RTW Investments has trimmed its stake in Cogent Biosciences, Inc. (NasdaqGS: COGT) by 28.1%. According to its latest Form 13F filing with the SEC, the fund sold 2,133,566 shares, bringing its total holdings to 5,458,675 shares. The remaining shares are valued at approximately $180.7 million as of the reporting period.

What Changed in RTW Investments' Cogent Biosciences Position

RTW Investments reduced its position in Cogent Biosciences from 7,592,241 shares to 5,458,675 shares, a decrease of 2,133,566 shares or 28.1%. The current value of the holdings stands at around $180.7 million.

Other Institutional Activity in Cogent Biosciences

Other institutional investors have shown varied activity in Cogent Biosciences. FMR LLC increased its holdings slightly by 35,781 shares, ending with 23,122,748 shares valued at approximately $889.99 million. BlackRock, Inc. significantly boosted its position by 3,070,423 shares, holding a total of 16,045,014 shares worth about $617.57 million. Meanwhile, Deerfield Management Company maintained its stake with 9,043,903 shares valued at $348.10 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC each added new positions, holding 7,333,333 shares and 6,894,959 shares, respectively.

Cogent Biosciences Stock Snapshot

Shares of Cogent Biosciences traded near $33.10. The company boasts a market capitalization of approximately $5.66 billion. It has no meaningful P/E ratio as it is not currently profitable, with a forward P/E ratio of -34.63. The stock's 52-week range spans from $6.92 to $43.73, with a 50-day moving average of $34.73 and a 200-day moving average of $30.66. The company maintains a strong liquidity position with a current ratio of 15.14 and a quick ratio of 14.94, while its debt-to-equity ratio stands at 39.27.

Recent Earnings

Cogent Biosciences has not reported profitability, with a negative EPS of -$2.17. The company's net margin is currently at 0.0%, and it has a return on equity of -85.72%. Investors are looking ahead to the next earnings report, expected on August 4, 2026.

Insider Buying and Selling at Cogent Biosciences, Inc.

On June 9, 2026, several insiders, including Peter Evan Harwin and Todd Shegog, each purchased 17,901 shares. These transactions were not part of a planned trading program.

Analysts Set New Price Targets

Analysts remain optimistic about Cogent Biosciences. On May 6, 2026, HC Wainwright & Co. maintained a buy rating with a price target of $55.00. Jefferies also assumed a buy rating with the same target on March 16, 2026. The consensus among 12 analysts is a strong buy, with a mean target price of $54.25.

About Cogent Biosciences

Cogent Biosciences, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts. The company focuses on developing precision therapies for genetically defined diseases. Its lead product candidate, bezuclastinib, targets mutations in the KIT receptor tyrosine kinase. Cogent is also working on several other compounds targeting various genetic mutations.

Bottom Line

RTW Investments' decision to reduce its stake in Cogent Biosciences by 28.1% is part of its latest portfolio adjustments as reported in its 13F filing. While the stock remains volatile, it continues to draw interest from both institutional investors and analysts. As always, these filings are backward-looking and may not reflect the fund's current position.